Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis

Economic Evaluation of Voriconazole for the Treatment of Candidemia in Canadian Adults

(2016) Coleman Rotstein et al.   Canadian Journal of Infectious Diseases & Medical Microbiology

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp.

(2009) E Geoffrey Playford et al.   CRITICAL CARE MEDICINE

Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemicCandidainfections in the UK

(2009) M. K. Sidhu et al.   CURRENT MEDICAL RESEARCH AND OPINION

Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia

(2009) D. Al-Badriyeh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The costs and cost-effectiveness of an integrated sepsis treatment protocol

(2008) Daniel Talmor et al.   CRITICAL CARE MEDICINE

Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany

(2008) O. A. Cornely et al.   CURRENT MEDICAL RESEARCH AND OPINION

Recommendations for the treatment of established fungal infections

(2008) K. A. Thursky et al.   INTERNAL MEDICINE JOURNAL

Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia

(2008) D. Al-Badriyeh et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy

(2008) Wiro B. Stam et al.   VALUE IN HEALTH